Birchview Capital, LP Biogen Inc. Transaction History

Birchview Capital, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$187.54 - $223.02 $1.89 Million - $2.25 Million	-10,100 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$193.77 - $244.14 $484,425 - $610,350	-2,500 Reduced 19.84%	10,100 $2.13 Million
Q3 2021 Nov 12, 2021	BUY	$282.99 - $369.05 $141,495 - $184,525	500 Added 4.13%	12,600 $3.57 Million
Q4 2020 Feb 09, 2021	BUY	$236.26 - $355.63 $259,886 - $391,193	1,100 Added 10.0%	12,100 $2.96 Million
Q1 2020 May 12, 2020	BUY	$268.85 - $341.04 $1.61 Million - $2.05 Million	6,000 Added 120.0%	11,000 $3.48 Million
Q2 2019 Aug 06, 2019	BUY	$219.29 - $241.72 $548,225 - $604,300	2,500 Added 100.0%	5,000 $1.17 Million
Q4 2018 Feb 06, 2019	BUY	$278.5 - $352.75 $139,250 - $176,375	500 Added 25.0%	2,500 $752,000
Q1 2018 May 07, 2018	BUY	$260.13 - $367.91 $260,130 - $367,910	1,000 Added 100.0%	2,000 $548,000
Q3 2017 Nov 02, 2017	BUY	$281.15 - $329.69 $281,150 - $329,690	1,000	1,000 $313,000

1,037

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.6B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Birchview Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Birchview Capital, LP with notifications on news.